Director, ADME
YOUR ROLE:
As Director , ADME at Enveda, you’ll build and lead a high-impact ADME function that helps move discovery programs from promising chemistry to development-ready candidates. Reporting to the Chief Scientific Officer, you’ll partner closely with Medicinal Chemistry, Pharmacology, Non-Clinical, and other scientific teams to define DMPK strategy, generate decision-quality data, and accelerate candidate selection.
This is a high-impact leadership opportunity where you’ll shape Enveda’s ADME capabilities, scientific strategy, and team while directly influencing the advancement of our drug discovery pipeline.
WHAT YOU’LL DO:
Provide scientific leadership on ADME-SAR, partnering with Medicinal Chemistry teams to improve druggability and guide compound optimization.
Define and execute DMPK strategies across early discovery, lead optimization, and candidate selection.
Lead the design, execution, interpretation, and communication of in vitro and in vivo ADME studies, including PK/PD strategy and bioanalytical methods.
Build and lead a high-performing ADME organization, including talent development, SOPs, scientific capabilities, lab operations, CAPEX/OPEX planning, data integrity, quality, safety, and audit readiness.
WHAT WE’RE LOOKING FOR:
PhD in Pharmaceutical Sciences, Pharmacokinetics, Drug Metabolism, or a related scientific discipline.
15+ years of post-PhD experience in ADME/DMPK within drug discovery or development, with deep expertise across the discovery lifecycle.
Demonstrated experience building and leading ADME/DMPK functions, including scientific strategy, team development, laboratory capabilities, and external partnerships.
Strong scientific judgment and understanding of bioanalysis, PK/PD, regulatory expectations, data integrity, safety, and quality requirements, combined with the ability to influence and collaborate across functions.
We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you.
ABOUT ENVEDA:
We’re a clinical-stage, AI-enabled biotech discovering medicines four times faster than the industry standard.
We recently raised $150M in a Series D, reached unicorn status, and advanced our first drug into Phase 2 trials.
Forbes named us one of America's Best Startup Employers. Newsweek recognized us as a Top 100 Most Loved Workplace. We’re building something rare - and we’re just getting started!